- Cabozantinib monotherapy is well-tolerated and shows activity in patients with platinum-refractory metastatic urothelial carcinoma with measurable disease.
Why this matters
- This is the first study to investigate a therapy targeting both angiogenic pathways and the MET receptor in this setting.
- Findings provide a rationale for combining cabozantinib with immunotherapeutic strategies in future research.
- Phase 2 trial.
- 68 patients with metastatic platinum-refractory urothelial carcinoma received cabozantinib.
- Funding: National Cancer Institute Intramural Program; Cancer Therapy Evaluation Program.
- The median follow-up was 61.2 months.
- In 42 evaluable patients with metastatic urothelial carcinoma with measurable disease:
- 1 complete and 7 partial responses were reported.
- Overall response rate was 19%.
- Median PFS was 3.7 (95% CI, 3-6) months.
- The most common grade 3-4 adverse events were fatigue, hypertension, proteinuria, and hypophosphatemia.
- No treatment-related deaths were reported.
- Open label, no control group.